Technological seminar, Inovotion - A unique in vivo assay platform for your oncology and immuno-oncology drug candidates

Jean Viallet

21 June 2022

Séminaire
Jean Viallet

Infos pratiques

11:00 - 12:00
Salle Rosalind Franklin
Professionnel de recherche
Accès mobilité réduite

INOVOTION is a biotech company (spin-off from Grenoble-Alpes University) which developed a unique in vivo technology dedicated to efficacy and toxicity evaluations for oncology and immuno-oncology treatments.
This unique platform provides early analysis of drug candidates from small molecules to biologics, before the classical preclinical stage. By eliminating low-value molecules early, INOVOTION accelerates the drug discovery process, increases the R&D productivity, and reduces its costs.

 

INOVOTION built this xenograft model using chicken embryo because it has tremendous benefits: fast, robust, affordable, and predictive. These in vivo assays will save time and give a clear competitive advantage to public and private researchers.

 

This next generation of in vivo efficacy and toxicity tests covers fours main aspects:

. Efficacy assays for anti-cancer treatments including antibodies and immune-checkpoints
. Early Toxicity assays for drug candidates
. Target Validation in oncology
. Multi-Cancer Screening to (re)positioning a treatment

Prof. Jean Viallet, Scientific Director, will present you this unique approach during this scientific conference.

 

 “We help chemists and biologists from Universities, Institute, Hospital and Companies to validate a target and/or develop treatments by getting them through in vivo evaluation, while staying within their budget. Our innovative technology allows rapid Go/No Go decisions.” Prof. Jean Viallet.

invited by Camille Faure

Inovotion recent results in literature

Paul Garcia, Yan Wang, Jean Viallet, and Zuzana Macek Jilkov. The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies. Frontiers in Immunology. 2021 November 19. 12:791081.

Marco Fiorillo, Béla Ózsvári, Federica Sotgia, Michael P Lisanti. High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy. Frontiers in Oncology. 2021 October 15. 11:740720.

Marco Fiorillo, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, Michael P Lisanti. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death & Differentiation. 2021 September. 28(9):2797-2817.

Béla Ózsvári, Luma G. Magalhães, Joe Latimer, Jussi Kangasmetsa, Federica Sotgia, Michael P. Lisanti. A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity. Frontiers in Oncology. 2020 September 15. 10:1528.

Mark W Nachtigal, Paris Musaphir, Shiv Dhiman, Alon D Altman, Frank Schweizer, Gilbert Arthur. Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo. Translational Oncology. 2021 Aug 11.1 4(11):101203

Camillo Sargiacomo, Sophie Stonehouse, Zahra Moftakhar, Federica Sotgia, Michael P Lisanti. MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo. Frontiers in Oncology. 2021 July 30. 11:678343.

Serah Kimani, Suparna Chakraborty, Ikponmwosa Irene, Jo de la Mare, Adrienne Edkins, André du Toit, Ben Loos, Angelique Blanckenberg, Annick Van Niekerk, Leticia V Costa-Lotufo, K N ArulJothi, Selwyn Mapolie, Sharon Prince. The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity. Biochemical Pharmacology. 2021 May 9. 190:114598.

Konstantin Byrgazov , Claes Anderson, Benjamin Salzer, Eva Bozsaky, Rolf Larsson, Joachim Gullbo, Manfred Lehner, Fredrik Lehmann, Ana Slipicevic, Leo Kager, Mårten Fryknäs and Sabine Taschner-Mandl. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Therapeutic Advances in Medical Oncology. 2020 July 29. 12:1758835920937891.

Guillaume Marcio, François Hermetet, Fabrice Neiers, Burhan Uyanik, Lucile Dondaine, Alexandre M M Dias, Laurène Da Costa, Mathieu Moreau, Pierre-Simon Bellaye, Bertrand Collin, Jessica Gobbo, Loïc Briand, Renaud Seigneuric, Olivier Kitten, Mathieu Cinier, Carmen Garrido. Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer. Cancer Therapy and Prevention. 2021 June 15. 148(12):3019-3031.

Serah Kimani, Suparna Chakraborty, Ikponmwosa Irene, Jo de la Mare, Adrienne Edkins, André du Toit, Ben Loos, Angelique Blanckenberg, Annick Van Niekerk, Leticia V Costa-Lotufo, K N ArulJothi, Selwyn Mapolie, Sharon Prince. The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity. Biochemical Pharmacology. 2021 May 9. 190:114598.

Héloïse M. Leclair, Nina Tardif, Anaïs Paris, Marie-Dominique Galibert, Sébastien Corre. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors. International Journal of Medical Sciences. 2020 July 16. 21(14):5025.

Achkar I, Kader S, Dib S, Junejo K, Al-Bader SB, Hayat S, Bhagwat A, Rousset X, Wang Y, Viallet J, Suhre K, Halama A. Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo. Metabolites. 2020 June 28. 10(7):E268.

Signetti L, Elizarov N, Simsir M, Paquet A, Douguet D, Labbal F, Debayle D, Di Giorgio A, Biou V, Girard C, Duca M, Bretillon L, Bertolotto C, Verrier B, Azoulay S, Mus-Veteau I. Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf V600E Melanoma. Cancers. 2020 Jun 9. 12(6):1500.